PEGASYS RBV DIN 02253429
Status: Cancelled Post Market
Holder: HOFFMANN-LA ROCHE LIMITED
Health Canada record
| Active ingredient(s) | PEGINTERFERON ALFA-2A 180 MCG; RIBAVIRIN 200 MG |
|---|
| Dosage form | Tablet; Solution |
|---|
| Route | Subcutaneous; Oral |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L03AB61 PEGINTERFERON ALFA-2A, COMBINATIONS |
|---|
| Original market date | 26-May-2004 |
|---|
| Current status date | 10-Jul-2018 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEGINTERFERON ALFA-2A
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02248077 | PEGASYS | PHARMAAND GMBH | Solution | PEGINTERFERON ALFA-2A 180 MCG | Marketed |
| 02248078 | PEGASYS | HOFFMANN-LA ROCHE LIMITED | Solution | PEGINTERFERON ALFA-2A 180 MCG | Cancelled Post Market |
| 02253410 | PEGASYS RBV | HOFFMANN-LA ROCHE LIMITED | Tablet; Solution | PEGINTERFERON ALFA-2A 180 MCG; RIBAVIRIN 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 3269 | 2004-05-10 | New Drug Submission (NDS) | |
Request a quote for PEGASYS RBV
How to read a Canadian DIN record